New hope for breast cancer patients with brain tumors: drug trial targets hard-to-treat spread
NCT ID NCT05866432
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called datopotamab-deruxtecan (Dato-DXd) in 20 people with triple-negative breast cancer that has spread to the brain. The goal is to see if the drug can shrink brain tumors. Participants must have newly diagnosed or worsening brain metastases. The study is currently recruiting.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER STAGE IV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AKH Universitaetsklinikum Vienna, Department f. Internal medicine I, oncology
RECRUITINGVienna, State of Vienna, 1090, Austria
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New combo attack on aggressive breast cancer brain tumors shows promise in early trial
- New hope for stage IV breast cancer: adding surgery or radiation to targeted therapy
- Freezing tumors to supercharge immunotherapy: new hope for aggressive breast cancer?
- Triple threat: new combo aims to tackle tough breast cancer
- New trial aims to cure HER2+ breast cancer with smart, adaptive therapy
- Cherry juice tested as shield against chemo nerve pain